PD-1 and PD-L1 Inhibitors Market Expands with 200+ Drugs in Development Across 180+ Companies
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
A new competitive landscape report documents exhaustive insights into global developments in PD-1 and PD-L1 inhibitors, covering over 180 companies and 200 drugs. The report evaluates therapeutics by product type, stage, route of administration, and molecule type, also highlighting inactive pipelines.
PD-1 and PD-L1 inhibitors, pivotal components of immunotherapy, enhance the immune system's capability against cancer cells. By blocking the interaction between PD-1 receptors on T cells and PD-L1 on tumor cells, these inhibitors reinvigorate the immune response, offering improved outcomes in cancers like melanoma and lung cancer. Key drugs in this class, such as nivolumab and pembrolizumab, are crucial in reactivating T cell involvement and overcoming cancer evasion mechanisms.
In February 2025, Innovent Biologics' IBI363 received FDA Fast Track Designation for advanced squamous non-small cell lung cancer post immunotherapy and chemotherapy. Shanghai Henlius Biotech's HLX43 completed Phase II in February 2025. Pfizer's sasanlimab met primary endpoints in its Phase III CREST trial in January 2025. AstraZeneca's Rilvegostomig was approved for a Phase III clinical study in December 2024. The FDA widened Jemperli's approval for endometrial cancer treatment in August 2024.
Among marketed therapies, Merck has achieved significant success through Keytruda in treating cancers like melanoma and NSCLC. GSK leverages Jemperli in ongoing research, emphasizing substantial R&D in oncology across multiple cancer types.
Pipeline developments include AstraZeneca's Rilvegostomig, a bi-specific antibody under Phase III trials targeting lung carcinoma and gastric cancers. Pfizer's sasanlimab, a PD-1 inhibitor, is in Phase III trial stage for bladder cancer treatment. Incyte Corporation's INCB 099280, an orally administered PD-L1 inhibitor, is advancing through Phase II trials for squamous cell carcinoma.
Suzhou Zelgen Biopharmaceuticals' ZG005 targets PD-1 and TIGIT, showing promise in Phase II for hepatocellular carcinoma. ImmVira Pharma's C5252, developed via the OvPENS platform, is a next-generation oncolytic virus therapy in Phase I for glioblastoma.
The competitive report includes a comprehensive commercial assessment, analyzing collaborations and licensing trends. The report covers unmet needs and the emerging therapeutic landscape, providing critical insights into various treatment stages and technological innovations.